Apogee Therapeutics (APGE) Competitors $40.18 -0.16 (-0.40%) Closing price 04:00 PM EasternExtended Trading$40.18 +0.01 (+0.01%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock APGE vs. BBIO, BPMC, ELAN, LEGN, TGTX, TLX, VRNA, LNTH, AXSM, and GRFSShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), Lantheus (LNTH), Axsome Therapeutics (AXSM), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. BridgeBio Pharma Blueprint Medicines Elanco Animal Health Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Verona Pharma Lantheus Axsome Therapeutics Grifols BridgeBio Pharma (NASDAQ:BBIO) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations. Is BBIO or APGE more profitable? Apogee Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Apogee Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-241.44% N/A -75.69% Apogee Therapeutics N/A -21.81%-20.94% Do insiders and institutionals hold more shares of BBIO or APGE? 99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 42.8% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, BBIO or APGE? BridgeBio Pharma has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Does the MarketBeat Community believe in BBIO or APGE? BridgeBio Pharma received 151 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 72.47% of users gave BridgeBio Pharma an outperform vote. CompanyUnderperformOutperformBridgeBio PharmaOutperform Votes17972.47% Underperform Votes6827.53% Apogee TherapeuticsOutperform Votes28100.00% Underperform VotesNo Votes Do analysts rate BBIO or APGE? BridgeBio Pharma presently has a consensus price target of $57.09, indicating a potential upside of 73.85%. Apogee Therapeutics has a consensus price target of $94.60, indicating a potential upside of 135.44%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Apogee Therapeutics is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, BBIO or APGE? Apogee Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Apogee Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$127.42M48.94-$535.76M-$3.53-9.30Apogee TherapeuticsN/AN/A-$83.99M-$3.60-11.16 Does the media prefer BBIO or APGE? In the previous week, BridgeBio Pharma had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 16 mentions for BridgeBio Pharma and 13 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.33 beat BridgeBio Pharma's score of 0.80 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryApogee Therapeutics beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks. Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$2.92B$5.36B$8.39BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-16.6030.5126.5919.72Price / SalesN/A400.93391.61116.20Price / CashN/A168.6838.2534.62Price / Book5.363.286.794.51Net Income-$83.99M-$72.17M$3.23B$248.18M7 Day Performance0.83%4.32%4.03%1.14%1 Month Performance22.31%7.68%12.22%15.07%1 Year Performance-18.35%-28.08%16.76%6.59% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics2.1728 of 5 stars$40.18-0.4%$94.60+135.4%-23.0%$1.85BN/A-16.6091Positive NewsGap DownBBIOBridgeBio Pharma4.6353 of 5 stars$35.68+4.4%$57.09+60.0%+14.2%$6.77B$127.42M-12.52400Positive NewsInsider TradeBPMCBlueprint Medicines2.6687 of 5 stars$100.31+3.2%$126.56+26.2%-1.2%$6.48B$562.12M-92.88640Positive NewsELANElanco Animal Health3.5226 of 5 stars$12.82+7.2%$15.00+17.0%-23.1%$6.36B$4.43B32.049,800Analyst ForecastLEGNLegend Biotech3.5601 of 5 stars$32.38+1.9%$78.82+143.4%-33.8%$5.95B$627.24M-34.081,070News CoverageAnalyst RevisionGap UpTGTXTG Therapeutics3.8221 of 5 stars$34.99+4.0%$40.80+16.6%+115.2%$5.56B$386.39M-349.87290Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.25-5.4%$22.00+35.4%N/A$5.49B$783.21M0.00N/APositive NewsGap UpVRNAVerona Pharma1.8852 of 5 stars$67.53+6.6%$81.50+20.7%+484.7%$5.48B$118.54M-35.1730Positive NewsLNTHLantheus4.458 of 5 stars$79.52-2.7%$132.67+66.8%-7.3%$5.45B$1.54B13.23700Positive NewsHigh Trading VolumeAXSMAxsome Therapeutics4.7267 of 5 stars$110.16+2.2%$172.14+56.3%+39.7%$5.42B$432.16M-18.39380Positive NewsInsider TradeGRFSGrifols3.2195 of 5 stars$7.73+8.9%N/A+4.7%$5.31B$7.21B6.6126,300Positive News Related Companies and Tools Related Companies BBIO Competitors BPMC Competitors ELAN Competitors LEGN Competitors TGTX Competitors TLX Competitors VRNA Competitors LNTH Competitors AXSM Competitors GRFS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APGE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APGE Stock Free APGE Stock Alerts